Citations

Showing 10 of 108119 citations.

P533 Ustekinumab therapeutic drug monitoring in Crohn’s disease patients with loss of response
Heron, Valérie , Bitton, Alain , Seidman, Ernest G. , Battat, Robert , Lemieux, Carolyne, Afif, Waqqas , Bessissow, Talat , Lakatos, Péter L. , Jain, Anjali , Germain, Pierre

Mayo Clinic

Journal of Crohn's and Colitis | January 25, 2019 | Volume: 13 | Issue: Supplement_1 | Pages: S379-S380

10.1093/ecco-jcc/jjy222.657 Get It

P479 Analysis of haematological changes in tofacitinib-treated patients with ulcerative colitis across Phase 3 induction and maintenance studies
Lichtenstein, Gary R. , Soonasra, Arif, Nduaka, Chudi, Wang, L, Lawendy, Nervin, Chan, Geoffrey , Moore, Gregory , Kwok, Kenneth , Su, C, Loftus, Edward V.

Mayo Clinic

Journal of Crohn's and Colitis | January 25, 2019 | Volume: 13 | Issue: Supplement_1 | Pages: S351-S352

10.1093/ecco-jcc/jjy222.603 Get It

P136 Association between histological indices and ulcerative colitis activity measures among patients in the HICKORY (etrolizumab) open-label induction cohort
Feagan, Brian G. , Pai, Rish K. , Arulmani, Udayasankar, Boruvka, Audrey, Oh, Youngjun, Scherl, Alexis , Scalori, Astrid, Arrisi, Pablo, Tole, Swati, Peyrin‐Biroulet, Laurent , Rubin, David T.

Mayo Clinic

Journal of Crohn's and Colitis | January 25, 2019 | Volume: 13 | Issue: Supplement_1 | Pages: S157-S158

10.1093/ecco-jcc/jjy222.260 Get It

P313 Impact of upadacitinib on the general clinical condition of patients with Crohn’s disease (CD): data from the randomised CELEST study
Pugatch, David, Goteti, S, Lacerda, Ana P. , Loftus, Edward V. , Rubin, David T. , Panés, Julián , Zhou, Wen , Travis, Simon

Mayo Clinic

Journal of Crohn's and Colitis | January 25, 2019 | Volume: 13 | Issue: Supplement_1 | Pages: S257-S257

10.1093/ecco-jcc/jjy222.437 Get It

P283 Bowel urgency in patients with moderate to severe ulcerative colitis: prevalence and correlation with clinical outcomes, biomarker levels, and health-related quality of life from U-ACHIEVE, a Phase 2b study of upadacitinib
Louis, Édouard , Reinisch, Walter , Cataldi, Fabio, Lee, W-J, Ghosh, Subrata , Louis, Edouard , Loftus, Edward V. , Reinisch, Walter , Zhou, Wen , Lee, W-J, Panés, Julián

Mayo Clinic

Journal of Crohn's and Colitis | January 25, 2019 | Volume: 13 | Issue: Supplement_1 | Pages: S240-S241

10.1093/ecco-jcc/jjy222.407 Get It

Hepatitis C Virus: No Longer a Barrier to Oncology Care
Laique, Sobia N. , Vargas, Hugo E. , Vargas, Hugo E

Mayo Clinic

American Journal of Gastroenterology | January 25, 2019 | Volume: 114 | Issue: 2 | Pages: 207-208

10.14309/ajg.0000000000000095 | PMID 30676362 Get It

Abstract: Historically, hepatitis C virus infection has posed a barrier to cancer therapies and enrollment in clinical trials for oncology patients. Oral direct acting antivirals now allow most patients, previously considered difficult to treat to be effectively (>95% sustained virologic response) and safely cured.
Same- vs Different-Hospital Readmissions in Patients With Cirrhosis After Hospital Discharge
Okafor, Philip N. , Nnadi, Augustine K., Okoli, Okwuchukwu, Huang, Alice E. , Nwaiwu, Obioma

Mayo Clinic

American Journal of Gastroenterology | January 25, 2019 | Volume: 114 | Issue: 3 | Pages: 464-471

10.14309/ajg.0000000000000050 | PMID 30676364 Get It

INTRODUCTION: There is a lack of data on the impact of readmission to the same vs a different hospital following an index hospital discharge in cirrhosis patients. METHODS: We sought to describe rates and predictors of different-hospital readmissions (DHRs) among patients with cirrhosis and also determine the impact on cirrhosis outcomes including all-cause inpatient mortality and hospital costs. Using the national readmissions database, we identified cirrhosis hospitalizations in 2013. Regression analysis was used to determine the predictors of DHRs. A time-to-event analysis was performed to assess the impact on subsequent readmissions and all-cause inpatient mortality. RESULTS: In 2013, there were 109,039 cirrhosis readmissions with 67% of these being same-hospital readmissions and 33% being DHRs ( P < 0.001). Two percent of readmitted patients were treated at ≥4 different hospitals. The 30-day readmission rate was 29.1%. Predictors of DHR included Medicaid payer (adjusted odds ratio [OR] 1.07, 95% confidence interval [95% CI] 1.01–1.14), age (OR 0.98, 95% CI 0.978–0.982), elective admission (OR 1.09, 95% CI 1.01–1.17), hepatic encephalopathy (OR 1.20, 95% CI 1.16–1.25), hepatorenal syndrome (OR 1.09, 95% CI 1.03–1.16), and low socioeconomic status (OR 1.15, 95% CI 1.06–1.25). No difference was observed in 30-day readmission risk following a DHR (adjusted hazard ratio 1.044, 95% CI 0.975–1.118). In addition, there was no increased risk of inpatient death observed during a DHR within 30 days (adjusted hazard ratio 1.08, 95% CI 0.94–1.23). However, patients with DHR had significantly higher hospital costs and length of stay. CONCLUSIONS: Majority of cirrhosis readmissions are same-hospital readmissions. Different-hospital readmissions do not increase the risk of 30-day readmissions and inpatient mortality but are associated with higher hospital costs.
Research participation provides adolescents and parents a launching pad for conversations
Francis, Jenny , Landers, Sara E. , Breitkopf, Carmen Radecki , Mauro, Christine , Catallozzi, Marina , Rosenthal, Susan L. , Chang, Jane Pei‐Chen

Mayo Clinic

Sexual Health | January 25, 2019 | Volume: 16 | Issue: 2 | Pages: 198-199

10.1071/sh18195 | PMID 30678749 Get It

Little is known about whether adolescent participation in sexual health research prompts adolescents and parents to have conversations about sensitive topics. One year after being presented with a hypothetical microbicide safety study, 248 adolescent–parent dyads were asked about conversations they may have had after their initial study visit. Sixty-three per cent of adolescents and 82% of parents reported having a conversation about the study. A launching conversation about broader topics (e.g. risk behaviours) was reported by 8% of adolescents and 17% of parents. Because there is evidence that conversations are occurring, researchers could provide guidance to help facilitate potentially sensitive discussions.
Perceptions regarding vasopressin use and practices in septic shock, and cost containment strategies
Rech, Megan A. , Daley, Mitchell J. , Devlin, John W. , Hodge, Emily K., Kooda, Kirstin , Lat, Ishaq , Personett, Heather A. , Roberts, Russel J. , Stollings, Joanna L. , Swanson, Joseph M. , Hammond, Drayton A , Rech, Megan A , Devlin, John W , Kooda, Kirstin J, Lat, Ishaq , Sacha, Gretchen , Bauer, Seth R

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | January 24, 2019 | Volume: 2 | Issue: 3 | Pages: 257-267

10.1002/jac5.1079 | PMID 38213315 Get It

BackgroundClinician preferences and practices regarding appropriate vasopressin use in light of its increased acquisition cost secondary to rebranding has not been evaluated or described since the most recent iteration of the Surviving Sepsis Campaign Guideline was published.ObjectiveTo assess vasopressin cost containment initiatives and pharmacists' opinions regarding appropriate vasopressin use.MethodsA scenario‐based survey was distributed to critical care and emergency medicine pharmacists. Responses were characterized using frequency and descriptive statistics. Categorical variables between those who implemented changes (Vasopressin Cost Consideration) and those who did not (Usual Care) were compared using chi‐square or Fisher's exact tests. McNemar's test was used to compare responses in clinical scenarios between Vasopressin Cost Consideration and Usual Care groups.ResultsAmong 1757 pharmacists surveyed, 200 (11.3%) responded. When respondents considered vasopressin cost and evidence (vs evidence alone), fewer respondents would use vasopressin adjunctively with norepinephrine (21% vs 26.6%, P = 0.031), to raise mean arterial pressure compared with epinephrine (65.2% vs 72.3%, P = 0.012), or to reduce norepinephrine infusion rates (71.4% vs 81.4%, P < 0.001), but would use with steroids (62.4% vs 28.3%, P < 0.001). Most (72%) respondents had implemented vasopressin cost containment and/or education initiatives. The Vasopressin Cost Consideration group respondents were more likely to initiate vasopressin at 0.03 units/minute without titrating (47.9% vs 33.9%, P = 0.045).ConclusionSince vasopressin was generically rebranded, most institutions have implemented at least one initiative to reduce vasopressin use and/or educate clinicians about its appropriate use. When vasopressin acquisition costs were considered, pharmacists recommended its use less frequently, particularly in clinical scenarios where its use is controversial.